Kantum Pharma

Kantum Pharma is a biopharmaceutical startup that aims to revolutionize the prevention and treatment of acute kidney injury (AKI). The company's slogan, “Developing groundbreaking therapies and innovative diagnostics to help clinicians prevent and treat acute kidney injury, potentially saving countless lives,” encapsulates its mission. Founded in 2016, the company operates in the biopharma, biotechnology, health care, and health and wellness sectors. Kantum Pharma's key initiatives include the development of KB-1801, a selective receptor antagonist-based therapeutic for preventing and treating AKI, especially following cardiovascular interventions. Additionally, the company is working on an innovative UDP-G diagnostic test to facilitate early identification of high-risk AKI patients. These initiatives show promise not only in cardiovascular incidents but also in conditions commonly seen in ICU settings such as sepsis, polytrauma, and nephrotoxicity. The company recently secured a significant $3.53M Series A investment on July 12, 2021, with funding from prominent investors including Broadview Ventures and 10X Venture. This investment will likely provide Kantum Pharma with the necessary resources to further develop and commercialize its groundbreaking therapies and diagnostics, positioning the company as a significant player in addressing the critical issue of AKI in the healthcare industry.